Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.13M Buy
8,098
+1,987
+33% +$201K 0.26% 71
2026
Q1
$270K Sell
6,111
-441
-7% -$20.2K 0.07% 150
2025
Q4
$242K Sell
6,552
-43,788
-87% -$1.65M 0.06% 152
2025
Q3
$1.69M Buy
50,340
+5,574
+12% +$135K 0.42% 54
2025
Q2
$1M Buy
44,766
+902
+2% +$18.7K 0.29% 71
2025
Q1
$996K Sell
43,864
-562
-1% -$12.3K 0.31% 69
2024
Q4
$891K Buy
44,426
+19,573
+79% +$441K 0.26% 77
2024
Q3
$583K Buy
24,853
+3,683
+17% +$92K 0.19% 87
2024
Q2
$674K Buy
21,170
+1,540
+8% +$50.5K 0.24% 83
2024
Q1
$867K Buy
19,630
+318
+2% +$14.2K 0.33% 67
2023
Q4
$970K Sell
19,312
-72
-0.4% -$2.92K 0.41% 63
2023
Q3
$677K Buy
19,384
+659
+4% +$23K 0.33% 59
2023
Q2
$626K Buy
+18,725
New +$588K 0.29% 68
2020
Q3
Sell
-4,196
Closed -$251K 78
2020
Q2
$251K Buy
+4,196
New +$251K 0.5% 56

Other funds holding INTC

Prostatis Group's INTC Position: Q2 2026 in Review

Prostatis Group increased its Intel (INTC) stake by 33% in Q2 2026, buying an estimated $201K and bringing the position to 8,098 shares worth $1.13M. The position accounts for 0.26% of the portfolio, ranked #71.

Prostatis Group first reported a position in INTC in Q2 2020 and has held it in 14 quarters since. The position peaked at $1.69M in Q3 2025. 3,559 funds tracked by Wall St. Rank hold INTC as of Q2 2026.

  • Prostatis Group held 8,098 shares of Intel worth $1.13M as of Q2 2026.
  • Prostatis Group bought 1,987 Intel shares in Q2 2026, an estimated $201K.
  • Intel made up 0.26% of Prostatis Group's portfolio in Q2 2026, its #71 holding.
  • Prostatis Group first reported a position in Intel in Q2 2020 and has held it in 14 quarters since.
  • Prostatis Group's Intel position peaked at $1.69M in Q3 2025.
  • 3,559 funds tracked by Wall St. Rank held Intel as of Q2 2026.

Based on Prostatis Group's 13F filing for Q2 2026, filed 14 Aug 2026.